Kenny-phase i single ascending dose study-BPN-19302 (AZD4041) protocol development and finalization and database build and bioanalytical methods development for clinical trial execution
Ended Awarded Last action
- Contract number
- 75N95019F00088
- Awardee
-
PPD Development LP UEI ZANENSW6C665
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,931,644
Award facts
- Opportunity
-
- NIHNINDS1904 Solicitation number
- Contract value 92% obligated
-
- $1,931,644.00 Current, with exercised options
- $2,104,350.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Neurological Disorders and Stroke National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Cape Fear, NC 28401, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $476,848 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $1,184,807 | |
| Original award | $269,989 |
About this award
This is a cost-plus-fixed-fee Delivery Order awarded by the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to PPD Development LP, a global contract research organization (CRO). The $2,104,350.00 task order is for protocol development, database build, and bioanalytical methods development in support of a Phase I clinical trial for the neurotherapeutic drug candidate AZD4041. The award is part of a larger Indefinite Delivery/Indefinite Quantity (ID/IQ) contract vehicle for Phase I clinical trials of neurotherapeutics. PPD has been awarded over $500 million in prime federal contracts and has participated as a subcontractor on federal grants and contracts with agencies like the Department of Health and Human Services, Department of Defense, and National Cancer Institute.
Quick answers
Who was awarded contract 75N95019F00088?
75N95019F00088 was awarded to PPD Development LP by National Institute on Drug Abuse (National Institutes of Health) on July 1, 2019.
How much is contract 75N95019F00088 worth?
The government has obligated $1,931,644 on 75N95019F00088. Its potential value, with all options, is $2,104,350.
Which agency awarded contract 75N95019F00088?
National Institute on Drug Abuse (National Institutes of Health) awarded 75N95019F00088, with funding from National Institute of Neurological Disorders and Stroke (National Institutes of Health).
Is contract 75N95019F00088 an order under another contract?
Yes. 75N95019F00088 is a delivery order under HHSN271201600005I, an indefinite delivery contract, on Phase I Clinical Trials for Development of Neurotherapeutics.
Was contract 75N95019F00088 competed?
The extent of competition for 75N95019F00088 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award